COVID-19 Pandemic: How Robust is your Pharmaceutical Supply Chain?

2020 will be remembered for a long time as a time that changed our personal and professional lives. From R&D through manufacturing to distribution, the pandemic is impacting the pharmaceutical sector. The industry has been invigorated in recent months but is also being compromised, most notably through supply chain disruption. Even as in-country restrictions are lifted, the challenge continues.

Following Brexit preparation stockpiling, the current situation has highlighted the importance of supply chain flexibility.  Despite best efforts, supply problems can and will happen. The industry requires rapid change and as more trials take place and new therapies are trialled the supply chain will be forced to be flexible and react to current and future demands.

FDAS is part of the UK’s pharmaceutical supply chain.  As a contract testing laboratory, we are uniquely positioned to address the challenges facing the pharma industry in the UK.  Providing state-of -the-art technology, efficiency and flexibility, we are effective in meeting regulatory requirements.


FDAS are a leading independent provider of Pharmaceutical QC Testing:

  • Raw Material Testing
  • Finished Product, Batch Release Testing
  • Stability Services

Larissa Taylor, Technical Director at FDAS said, “In the context of what is happening I think there is little doubt about the need to strengthen the supply chain. To ensure that critical and essential medicines will continue to be available in adequate amounts, there has never been a better time to partner with a contract testing laboratory dedicated to reducing lead-times and delivering supply chain stability.”

FDAS, being part of the Tentamus Pharma Group, has extensive industry expertise as well as a global network of modernized testing laboratories. Seamless communication including a single point of contact, virtual meetings and remote audits are at your service during these challenging times.  We are ready to help our customers get their potentially life-saving medicines to the patients that need them.

Über die Tentamus Group GmbH

Tentamus Group GmbH was founded in 2011. Tentamus is a global product and safety group with a core presence in Europe, UK, Israel, China, Japan, India and the USA. Accredited and licensed Tentamus Group tests, audits and consults on all products involving the human body (food & feed, pharmaceuticals & medical, agrosciences, cosmetics, agriculture & environment and nutraceutical & supplements). Tentamus Group is represented in over 65 locations worldwide. More than 2,500 highly-trained staff members work in over 2.5 million square feet of laboratory and office spaces. For further information please visit www.tentamus.com.

Firmenkontakt und Herausgeber der Meldung:

Tentamus Group GmbH
An der Industriebahn 5
13088 Berlin
Telefon: +49 (30) 206038-230
Telefax: +49 (30) 206038-190
http://tentamus.com

Ansprechpartner:
Larissa Taylor
Technical Director FDAS
Telefon: +44 (0) 115 912 4265
E-Mail: larissa.taylor@fdas.org
Für die oben stehende Pressemitteilung ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.

counterpixel